- Twist Bioscience expanded its antibody portfolio with Twist Express Screening Antibodies, a high-throughput cell-free service that produces purified full-length IgG and related formats with SPR binding characterization, with quantities from 5 µg to 20 µg and turnaround times starting at five days.
- Management reported better-than-expected revenue and raised the full-year outlook, crediting strong demand from pharmaceutical customers and AI-enabled drug discovery partners that are increasingly using Twist Bioscience for AI and machine learning driven antibody discovery workflows.
- The focus now turns to how Twist Bioscience's raised outlook and AI-focused antibody platform could influence the broader investment narrative.
Scan beyond Twist Bioscience and size up other AI-focused drug discovery players using the hand picked 36 healthcare AI stocks that could sit in the same workflow conversations.
What Is Twist Bioscience's Investment Narrative?
To own Twist Bioscience, you need to believe the firm can turn its DNA writing and antibody tools into a durable platform that pharma and AI drug discovery partners keep returning to. The Twist Express Screening Antibodies launch supports that idea by tightening the loop between sequence, protein, and binding data. Faster, cell free IgG production with SPR characterization can make Twist more embedded in AI driven workflows, which aligns with the recent uplift in demand management highlighted alongside the raised full year outlook.
The near term story still revolves around execution against heavy operating spend and the stated goal of breakeven adjusted EBITDA at the upcoming fiscal fourth quarter report. Twist Bioscience is unprofitable, carries a P/S of 25.2x versus lower peer and fair value multiples, and relies on higher risk funding with no customer deposits. That combination makes consistent order growth in areas like AI antibody discovery and the smooth ramp up of new services, including Twist Express Screening Antibodies, central to the thesis rather than a secondary detail.
Yet the picture becomes less straightforward once you consider ...
There's only one way to know the right time to buy, sell or hold Twist Bioscience. Head to Simply Wall St's company report for the latest analysis of Twist Bioscience's Fair Value.
Exploring Other Perspectives
Competition risk sits at the center of the most bearish Twist Bioscience narrative. While the headline today is new AI friendly antibody services, the lowest analysts were assuming revenue growth of 18.8% a year and still saw no profitability within three years. That is a much harsher setup. These views may shift after this launch.
Explore 3 other Twist Bioscience fair value estimates, including one that suggests it could be worth just $168.25.
Reach Your Own Conclusion
Don't just follow the ticker; dig into the data and build a conviction that's truly your own.
- A great starting point for your Twist Bioscience research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
- See our latest analysis for Twist Bioscience. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Twist Bioscience's overall financial health at a glance.
Looking For More Ideas Beyond Twist Bioscience?
If you want to pressure test your view on Twist Bioscience against what else is out there, use the Simply Wall St Screener to line it up alongside other potential opportunities that fit different risk and return profiles.
- For investors who care most about quality at a sensible entry point, compare Twist Bioscience against a curated set of 26 high quality undervalued stocks that have strong fundamentals and potentially more modest pricing.
- If capital preservation is higher on your list than aggressive upside, consider measuring it against a 32 resilient stocks with low risk scores to see how the risk profile stacks up.
- When you want sturdier balance sheets and cleaner fundamentals in your watchlist, broaden your research with a list of solid balance sheet and fundamentals (24 results) that can sit alongside higher risk ideas like Twist Bioscience.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com